HOME >> MEDICINE >> NEWS
Study results offer guidance in treatment

While many treatment approaches were found helpful, the authors report that the patients who were most successful in abstaining from alcohol 16 weeks after treatment were those prescribed naltrexone under medical management and those participating in a multi-session program of alcohol counseling delivered by a behavioral specialist.

The paper appears in the May 2 issue of the Journal of the American Medical Association and reports on the largest clinical trial ever conducted of pharmacologic and behavioral treatments for alcohol dependence.

"The most robust finding in the study is that those receiving any medication did much better than those who received no pills at all," says The Scripps Research Institute's Professor Barbara Mason, an author of the paper. "This should be a wakeup call. With less than one percent of those seeking help for alcohol dependence receiving a prescription, medication is underutilized. Medication for alcoholism can offer patients an advantage for their recovery, especially in a real-world setting."

Another important aspect of the study, says Mason, is that it offers new safety data on the prescription drugs used in the trial, naltrexone and acamprosate, which were administered at higher-than-standard doses. "We had no serious drug-related events during the course of the research," she says. "That fact should offer prescribing physicians a high degree of comfort."

About eight million individuals in the United States currently meet the diagnostic criteria for alcohol dependence, also called alcoholism, a leading preventable cause of morbidity and mortality and a major contributor to health care costs, according to the paper's background information. In primary care settings, the prevalence of alcohol use disorders ranges from 20 percent to 36 percent.

While several behavioral treatment programs and drugs now approved by the U.S. Food and Drug Administration had been shown effective for treating alc
'"/>

Contact: Keith McKeown
kmckeown@scripps.edu
858-784-8134
Scripps Research Institute
2-May-2006


Page: 1 2 3

Related medicine news :

1. Study, meta-analysis examine factors associated with death from heatstroke
2. Study says COPD testing is not measuring up
3. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
4. Study reveals gaps in vaccine financing for underinsured children
5. Study suggests nonpharmaceutical interventions may be helpful in severe influenza outbreaks
6. Study shows radiofrequency ablation highly effective in treating kidney tumors
7. Study says normal but out-of-control enzyme may be culprit that signals some cells to become cancer
8. Study finds HIV protease inhibitor drugs may adversely affect the scaffolding of the cell nucleus
9. Study outlines how stroke, head injury can increase risk of Alzheimers disease
10. Study identifies new regulator of fat metabolism
11. Study shows Diachrome improves blood sugar control in people with type 2 diabetes

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Study results offer guidance treatment

(Date:5/23/2013)... about to be tested in a clinical trial by ... for Alzheimer,s disease has failed to work with the ... according to results of a study by University of ... neuroscience affiliated with the Evelyn F. and William L. ... the importance of verifying promising research results before investing ...
(Date:5/23/2013)... negative" carries a poor prognosis, with limited treatment options. ... cells the way it,s supposed to. New research from ... to chemotherapy, and identifies a mechanism to rectify that. ... PhD, and his team at Western,s Schulich School of ... functions to promote the death of cancer cells by ...
(Date:5/23/2013)... New York (PRWEB) May 23, 2013 ... by C.R. Bard, Inc., continue to move forward in ... Southern District of West Virginia, Bernstein Liebhard LLP reports. ... Court denied a request by C.R. Bard to seal ... reveal trade secrets and other confidential, proprietary information about ...
(Date:5/23/2013)... Former United States Vice President Dick ... 's annual Paramedic Luncheon. , In front of ... praised Acadian's medics, saying, "I am delighted to be ... the Paramedic of the Year Award. I think it's ... of competition within a company like this because there ...
(Date:5/23/2013)... Jackson, TN (PRWEB) May 23, 2013 Spring ... fit, but what’s gotten into Jackson , the city ... variety of new fitness facilities and wellness centers has transformed ... in the state. , “In any city of vibrant, ... to improve or promote health,” said Kim White, owner of ...
Breaking Medicine News(10 mins):Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 3Health News:Acadian Ambulance Honors Paramedic of the Year at Annual Luncheon 2Health News:Grass Roots Wellness Initiative Builds Muscle in Jackson, Tennessee 2Health News:Grass Roots Wellness Initiative Builds Muscle in Jackson, Tennessee 3Health News:Grass Roots Wellness Initiative Builds Muscle in Jackson, Tennessee 4
(Date:5/23/2013)... , May 23, 2013  MGC Diagnostics Corporation ... global medical technology company, today scheduled a conference call ... of fiscal year 2013, ended April 30, 2013. The ... May 30, 2013. The Company will report financial results ... the markets close on Thursday, May 30, 2013. ...
(Date:5/23/2013)... 23, 2013  The need to add tissue ... was highlighted prominently at the 108 th ... in San Diego.  According to SonaCare Medical, a ... (HIFU) technology, the need for image-guided technologies to ... to consider minimally invasive ablative treatments, was addressed ...
(Date:5/23/2013)... 23, 2013  Spring Bank Pharmaceuticals, Inc., a biopharmaceutical ... infections, today announced that it has initiated dosing in ... once daily, oral therapy for the treatment of HCV ... and is designed to assess both the safety and ... first-in-class drug for the treatment of chronic HCV infections ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 2Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 3Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 4Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 5Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 6Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3
Cached News: